Egyptian International Pharmaceutical Investments (CAI:PHAR) Market Cap : E£6,219 Mil (As of Apr. 26, 2024)

View and export this data going back to 1995. Start your Free Trial

What is Egyptian International Pharmaceutical Investments Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Egyptian International Pharmaceutical Investments's share price for the quarter that ended in Dec. 2023 was E£36.5. Egyptian International Pharmaceutical Investments's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 149 Mil. Therefore, Egyptian International Pharmaceutical Investments's market cap for the quarter that ended in Dec. 2023 was E£5,430 Mil.

Egyptian International Pharmaceutical Investments's quarterly market cap increased from Jun. 2023 (E£3,481 Mil) to Sep. 2023 (E£5,110 Mil) and increased from Sep. 2023 (E£5,110 Mil) to Dec. 2023 (E£5,430 Mil).

Egyptian International Pharmaceutical Investments's annual market cap declined from Dec. 2021 (E£4,155 Mil) to Dec. 2022 (E£3,621 Mil) but then increased from Dec. 2022 (E£3,621 Mil) to Dec. 2023 (E£5,430 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Egyptian International Pharmaceutical Investments's Enterprise Value for Today is E£10,424 Mil.

Egyptian International Pharmaceutical Investments Market Cap Historical Data

The historical data trend for Egyptian International Pharmaceutical Investments's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egyptian International Pharmaceutical Investments Market Cap Chart

Egyptian International Pharmaceutical Investments Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Market Cap

Get a 7-Day Free Trial

6,591.85

4,239.43

4,155.23

3,620.71

5,429.59

Egyptian International Pharmaceutical Investments Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Market Cap	Get a 7-Day Free Trial															3,620.71	3,337.08	3,481.16	5,109.77	5,429.59

Competitive Comparison of Egyptian International Pharmaceutical Investments's Market Cap

For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Egyptian International Pharmaceutical Investments's Market Cap Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Egyptian International Pharmaceutical Investments's Market Cap distribution charts can be found below:

* The bar in red indicates where Egyptian International Pharmaceutical Investments's Market Cap falls into.

Egyptian International Pharmaceutical Investments Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Egyptian International Pharmaceutical Investments's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )	=	Share Price (A: Dec. 2023 )	*	Shares Outstanding (EOP) (A: Dec. 2023 )
	=	E£36.5	*	148.756
	=	E£5,430

Egyptian International Pharmaceutical Investments's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )	=	Share Price (Q: Dec. 2023 )	*	Shares Outstanding (EOP) (Q: Dec. 2023 )
	=	E£36.5	*	148.756
	=	E£5,430

Egyptian International Pharmaceutical Investments (CAI:PHAR) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Egyptian International Pharmaceutical Investments Market Cap Related Terms

Thank you for viewing the detailed overview of Egyptian International Pharmaceutical Investments's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Egyptian International Pharmaceutical Investments (CAI:PHAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Egyptian International Pharmaceutical Investments (CAI:PHAR) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

N/A

Address

1st Industrial Zone B1, EIPICO, 10th of Ramadan, EGY

Website

http://www.eipico.com.eg

Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, non-traditional dosage forms including soft gelatin capsules, lyophilized products, gels, sprayers and effervescent tablets. It exports its products to Arab countries, African, Asian and East European Countries. Its products portfolio includes antibiotics, anesthetics, analgesics, antihypertensives, cholesterol-lowering medications, ophthalmic products, blood substitutes and restoratives, dermatological drugs and vitamins. Some of its products are Vasotec, Co-vasotec, Flumox, and Cefotax.